The Medical Letter®

on Drugs and Therapeutics

Volume 68 March 16, 2026

ISSUE No. 1750

IN THIS ISSUE

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying, or any distribution of this material without permission to a nonsubscriber is prohibited.

Sharing a password with a nonsubscriber or otherwise making the contents of this site available to third parties is prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: Subscriptions, Site Licenses, Reprints
or call customer service at: 800-211-2769

The Medical Letter publications are protected by US and international copyright laws.
Forwarding, copying or any other distribution of this material is strictly prohibited.
For further information call: 800-211-2769

The Medical Letter®
on Drugs and Therapeutics

Volume 68 (Issue 1750) March 16, 2026

Take CME Exams

IN BRIEF

A Second Subcutaneous Furosemide Infusor *(Lasix ONYU)* for Heart Failure

The FDA has approved *Lasix ONYU* (SQ Innovation), a subcutaneous formulation of the loop diuretic furosemide administered via a wearable pump (on-body infusor), for treatment of edema in adults with chronic heart failure (HF). A similar product, *Furoscix,* is approved for treatment of edema in chronic HF or chronic kidney disease.[1] Furosemide has been available for years in oral and IV formulations for such use.

DIURETICS IN HF — Loop diuretics such as furosemide, bumetanide, and torsemide are more effective than thiazide-type diuretics such as hydrochlorothiazide for treatment of edema. They are often administered intravenously to achieve rapid diuresis in patients with acute edema that is resistant to oral diuretics. IV loop diuretics are inexpensive, but they generally must be given by a healthcare professional.[2]

EFFICACY AND SAFETY — FDA approval of *Lasix ONYU* was based on the results of a trial demonstrating that a pH-neutral, subcutaneous formulation of furosemide infused by a conventional pump over 5 hours (30 mg over 1 hour, then 12.5 mg/hour for the next 4 hours) had an absolute bioavailability similar to that of IV furosemide (one 80-mg bolus dose over 2 minutes), and produced equivalent diuresis. When the same subcutaneous formulation of furosemide was administered via the on-body infusor, plasma concentrations of the drug and diuresis were similar to those achieved with the conventional pump. Adverse effects associated with the on-body infusor included administration-site pain and local skin reactions.[3]

Table 1. Subcutaneous Furosemide Products

	Lasix ONYU	*Furoscix*
Manufacturer	SQ Innovation	SC Pharmaceuticals
Strength	80 mg/2.67 mL[1]	80 mg/10 mL[1]
Device	On-body infusor (a disposable unit plus a reusable unit[2])	Disposable on-body infusor
Dosage	80 mg SC over 5 hrs[3]	80 mg SC over 5 hrs[3]
Cost	$774.00[4]	$980.60[4]

1. Supplied as a pH-neutral solution in single-dose, prefilled cartridges for use with a wearable infusor device.
2. The reusable unit is packaged separately and requires charging; it should be replaced after 2 years or 48 uses.
3. The infusor device is preprogrammed to deliver 30 mg over 1 hour, then 12.5 mg/hour for 4 hours.
4. Approximate WAC for one kit containing one prefilled cartridge and one disposable device. The cost of *Lasix ONYU* includes the cost of the reusable unit. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. February 5, 2026. Reprinted with permission by First Databank, Inc. All rights reserved. ©2026. www.fdbhealth.com/drug-pricing-policy.

DOSAGE AND ADMINISTRATION — *Lasix ONYU* is not intended for chronic use; patients should be switched to oral diuretic therapy as soon as possible. After assembly and placement on the abdomen using an adhesive patch, the infusor will deliver 80 mg of furosemide subcutaneously over 5 hours (30 mg over the first hour, followed by 12.5 mg per hour for the next 4 hours). A second 80-mg infusion may be administered in a 24-hour period if needed. ■

1. In brief: Furoscix – a subcutaneous furosemide infusor for heart failure. Med Lett Drugs Ther 2023; 65:14.
2. Drugs for chronic heart failure. Med Lett Drugs Ther 2025; 67:81.
3. J Osmanska et al. A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies. Eur Heart J Cardiovasc Pharmacother 2024; 10:35.

PRESIDENT, EDITOR IN CHIEF: **Jean-Marie Pflomm, Pharm.D.**; *EDITOR IN CHIEF EMERITUS:* **Mark Abramowicz, M.D.**; *VICE PRESIDENT, ADMINISTRATION*: **Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School**; *ASSOCIATE EDITORS:* **Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D.** *CONSULTING EDITORS:* **Joanna Esterow, PA-C**, **Mordechai Sacks, DMSc, PA-C**, **Brinda M. Shah, Pharm.D.**, **F. Peter Swanson, M.D.**

CONTRIBUTING EDITORS: **Carl W. Bazil, M.D., Ph.D.**, Columbia University College of Physicians and Surgeons; **Ericka L. Crouse, Pharm.D., B.C.P.P., B.C.G.P., F.A.S.H.P., F.A.S.C.P.,** Virginia Commonwealth University; **Vanessa K. Dalton, M.D., M.P.H.**, University of Michigan Medical School; **Eric J. Epstein, M.D.**, Dartmouth Hitchcock Medical Center; **David N. Juurlink, BPhm, M.D., Ph.D.**, Sunnybrook Health Sciences Centre; **Richard B. Kim, M.D.**, University of Western Ontario; **Sandip K. Mukherjee, M.D., F.A.C.C.**, Yale School of Medicine; **Dan M. Roden, M.D.**, Vanderbilt University School of Medicine; **Esperance A.K. Schaefer, M.D., M.P.H.**, Harvard Medical School; **Arthur M. F. Yee, M.D., Ph.D., F.A.C.R.**, Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: **Susie Wong**; *EDITORIAL ASSISTANT:* **Karrie Ferrara**

FULFILLMENT AND SYSTEMS MANAGER: **Cristine Romatowski**; *EXECUTIVE DIRECTOR OF SALES:* **Elaine Reaney-Tomaselli**
EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: **Joanne F. Valentino**; *INTERIM PUBLISHER:* **Jean-Marie Pflomm, Pharm.D.**

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:
The Medical Letter, Inc.
2 Madison Ave, Ste 211
Larchmont, NY 10538
www.medicalletter.org

Customer Service:
Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
E-mail: custserv@medicalletter.org

Permissions:
To reproduce any portion of this issue, please e-mail your request to:
permissions@medicalletter.org

Subscriptions (US):
1 year – $179; $65 per year for students, interns, residents, and fellows in the US and Canada.
Reprints – $45 per issue or article

Site License Inquiries:
E-mail: SubQuote@medicalletter.org
Call: 800-211-2769
Special rates available for bulk subscriptions.

Get Connected:

Copyright 2026. ISSN 1523-2859